Bank of America set a $139.00 target price on Amedisys (NASDAQ:AMED) in a report published on Tuesday, September 18th. The brokerage currently has a buy rating on the health services provider’s stock.
A number of other analysts also recently issued reports on the stock. Cantor Fitzgerald began coverage on shares of Amedisys in a report on Thursday, September 13th. They set a neutral rating and a $117.00 price objective for the company. Canaccord Genuity began coverage on shares of Amedisys in a report on Thursday, September 13th. They set a neutral rating and a $117.00 price objective for the company. Royal Bank of Canada lifted their price objective on shares of Amedisys to $115.00 and gave the stock an outperform rating in a report on Friday, August 3rd. ValuEngine raised shares of Amedisys from a buy rating to a strong-buy rating in a report on Monday, July 30th. Finally, BidaskClub downgraded shares of Amedisys from a strong-buy rating to a buy rating in a report on Monday, June 18th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Amedisys has a consensus rating of Buy and a consensus price target of $95.38.
NASDAQ:AMED traded down $4.21 during trading hours on Tuesday, hitting $109.28. The stock had a trading volume of 640,680 shares, compared to its average volume of 312,146. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21. Amedisys has a one year low of $45.60 and a one year high of $127.38. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 49.45, a PEG ratio of 1.89 and a beta of 1.00.
In related news, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction on Wednesday, July 25th. The shares were sold at an average price of $94.18, for a total value of $37,483.64. Following the transaction, the insider now owns 12,216 shares in the company, valued at approximately $1,150,502.88. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. purchased a new position in shares of Amedisys in the second quarter valued at about $149,000. SG Americas Securities LLC purchased a new position in shares of Amedisys in the first quarter valued at about $123,000. Moneta Group Investment Advisors LLC purchased a new position in shares of Amedisys in the second quarter valued at about $181,000. Cubist Systematic Strategies LLC increased its position in shares of Amedisys by 1,086.0% in the second quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after acquiring an additional 2,172 shares during the period. Finally, Mount Yale Investment Advisors LLC purchased a new position in shares of Amedisys in the first quarter valued at about $151,000. Hedge funds and other institutional investors own 93.31% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Further Reading: What is a put option?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.